The buyback signals management's confidence in cash flow and valuation, but execution pace is at management's discretion. Monitor actual repurchase activity in future filings to gauge conviction; the authorization does not obligate PTC to buy shares.
PTCT drugs
PTCT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $68.12entry
- T+1 · 13d ago +1.25%α −0.40% · $68.97
- T+5 · 7d ago −5.84%α −5.26% · $64.14
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PTC Therapeutics announced a $500 million share repurchase program, representing ~9.3% of its $5.4B market cap. The buyback follows strong Q3 2026 results reported 5 days ago, where total revenue of $357.6M beat consensus and full-year product revenue guidance was raised to $960M-$990M.
Key Financial Metrics
Key Facts
- Board authorized up to $500 million in share repurchases
- Repurchases may be made through open-market transactions, privately negotiated deals, or accelerated share repurchases
- Authorization represents ~9.3% of current market cap ($5.4B)
- Follows Q3 2026 earnings beat (revenue $357.6M vs $305.0M consensus) and raised product revenue guidance to $960M-$990M
Financial Impact
$500 million share repurchase authorization, ~9.3% of market cap
Risk Factors
- Buyback may not be executed if cash needs arise for business development or operations
- Forward-looking statements subject to risks including pricing negotiations and regulatory uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302927094 |
Track record
29 reports on PTCT
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
- Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Viewing Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
- Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers